Market Access Impact: Renal Cell Carcinoma (EU5)

Market Access Impact: Renal Cell Carcinoma (EU5)

Code: FW-21072016-31 | Published: May-2016 | Pages: 0 | FirstWord
Price :
$4,995.00
USD

* Required Fields

$4,995.00

Details

Market barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand one of them?
We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European market when oncologists can’t prescribe freely. The result: 5 of those brands saw a net loss.
But 3 of them made significant net gains. Is your brand one of them?
You’ll learn how market barriers affect share for 8 major treatments from Bayer/Amgen, Novartis, Pfizer, and Roche.
Plus you’ll see which brands your brand is losing share to, which ones you’re taking it from, and why—information you can use to compete more effectively.


Get Answers to Key Questions about RCC Drug Brands


Afinitor (everolimus; Novartis): Afinitor takes market share from only two brands. Which two?
Avastin (bevacizumab; Roche): Which brand takes more than twice as much share from Avastin as any other?
Inlyta (axitinib; Pfizer): Would eliminating market barriers help Inlyta catch up to Afinitor?
Nexavar (sorafenib; Bayer/Amgen): Are doctors who don’t prescribe either brand more likely to consider Nexavar or Inlyta?
Proleukin (aldesleukin; Novartis): Which two barriers do more doctors experience with Proleukin than any other brand?
Sutent (sunitinib; Pfizer): Which barrier is responsible for nearly a quarter of Sutent’s impressive share gain?
Torisel (temsirolimus; Pfizer): Only one market barrier earns Torisel a net share gain. Which one?
Votrient (pazopanib; Novartis): Votrient and Afinitor are just about equally prescribed. Which brand has the edge in market share?

Top Takeaways


Barriers cost most brands market share: Five of the eight surveyed brands saw a net share loss due to barriers. Only three saw net gains.
Eliminating barriers would tighten up the market: Especially the top of the market, where it would make a big dent in the #1 brand’s lead.
Most brands are heavily prescribed: A majority of doctors prescribe nearly all of the brands surveyed. The most prescribed brand has almost a 10% lead over its nearest rival.
Clear market share winner: of the three brands that gain share due to market barriers, one gains more than twice as much as the closest competitor.
Barrier effect varies widely: The number of doctors who experience each market barrier varies widely from brand to brand.
Reimbursement and guidelines have the greatest impact: barriers related to reimbursement, patient type restrictions, and guidelines affect more prescriptions than any others.
Brand awareness is high: With one exception, no more than 1% of doctors surveyed were unaware of any given brand.
Overall market access is good: In Europe, market barriers affect less than 20% of prescription decisions.

Exploring Market Access Issues
Market Access Impact: RCC explores key issues affecting RCC drug manufacturers. You’ll learn:

How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest effect?
How barriers affect your brand:
How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge
We surveyed 150 medical oncologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents have:

Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between April 4th and 11th, 2016.


MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Table of Contents


1 Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary
2 Current Status of Interactions with Different Medical Affairs Teams
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3 Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4 Preferred Interaction Media, Frequency, and Suggestions for Improvement
4.1 Preferred interaction media and frequency, and suggestions for improvement
5 Appendix

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients